This study is in progress, not accepting new patients
A Study to Evaluate the Efficacy and Safety of Taldefgrobep Alfa in Participants With Spinal Muscular Atrophy
Summary
- Eligibility
- for people ages 4-21 (full criteria)
- Location
- at UCSD UCSF
- Dates
- study startedcompletion around
Description
Summary
Official Title
Details
Keywords
Eligibility
Locations
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Biohaven Pharmaceuticals, Inc.
- ID
- NCT05337553
- Phase
- Phase 3 research study
- Study Type
- Interventional
- Participants
- About 269 people participating
- Last Updated